Proteins and Peptides

22 Jun 2016 AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
22 Jun 2016 Cytonics Announces That Its Recombinant A2M Variants Attenuate Cartilage Degeneration in OA Models
17 Jun 2016 Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness
17 Jun 2016 Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial
15 Jun 2016 Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
14 Jun 2016 PharmaMar announces the start of a pivotal study with plitidepsin in angioimmunoblastic T-cell lymphoma
14 Jun 2016 Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
14 Jun 2016 Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial
13 Jun 2016 BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
13 Jun 2016 Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
13 Jun 2016 Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
13 Jun 2016 Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
13 Jun 2016 Intarcia Presents FREEDOM-2 Trial Results in Type 2 Diabetes Demonstrating Clinically Meaningful Superiority and Sustained Glucose Control and Weight Reduction for ITCA 650 vs. Januvia®: Oral Presentation at ADA 76th Scientific Sessions
13 Jun 2016 AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
13 Jun 2016 Janssen’s EPREX® (epoetin alfa) Demonstrates Effectiveness as a Treatment for Anaemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
13 Jun 2016 New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes
13 Jun 2016 Tresiba(R) (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
13 Jun 2016 Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes
13 Jun 2016 Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
10 Jun 2016 Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer
10 Jun 2016 Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial in Lupus
07 Jun 2016 Merz Receives CE Mark for Radiesse® (+) Lidocaine
07 Jun 2016 Cristalia obtains registration for first biotechnological pharmaceutical ingredient
07 Jun 2016 Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
07 Jun 2016 Neurovive Pharmaceutical: NeuroVive Announces CiPRICS Study Completes Enrolment

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing